Search SAMHSA Publications and Digital Products
Store Facets Summary
- Clear all filters
- Remove Professional Care Providers
- Remove Program Planners, Administrators, & Project Managers
- Remove Employers
- Remove Parents & Caregivers
- Remove Prevention Professionals
- Remove Guidelines or Manual
- Remove Advisory
- Remove People with Substance Use or Abuse Problems as Population Group
- Remove People in the Criminal Justice System
- Remove Practitioner/Professional
- Remove Buprenorphine
- Remove Nicotine
- Remove Marijuana
- Remove Opium
- Remove Oxycodone
Main page content
Published: August 2021The Executive Summary of this Treatment Improvement Protocol provides an overview on the use of the three Food and Drug Administration-approved medications used to treat opioid use disorder—methadone, naltrexone, and buprenorphine—and the other strategies and services needed to support recovery.
Published: July 2021This Treatment Improvement Protocol (TIP) reviews the use of the three Food and Drug Administration (FDA)-approved medications used to treat OUD—methadone, naltrexone, and buprenorphine—and the other strategies and services needed to support recovery for people with OUD. This is a revision.
Published: December 2019This guide supports health care providers, systems, and communities seeking to prevent marijuana use by pregnant women. It describes relevant research findings, examines emerging and best practices, identifies knowledge gaps and implementation challenges, and offers useful resources.
Published: August 2018This quick guide contains an overview of the challenges associated with tobacco cessation and the benefits of being tobacco-free for individuals as well as those of a smoke-free workplace. It also includes tips that substance use disorder treatment settings can use to implement their own tobacco cessation programs.